Doximity Inc (NYSE:DOCS) is a digital platform for medical professionals, offering tools for networking, telehealth, and news. It competes with other healthcare technology companies like Teladoc and Amwell. On February 9, 2026, Richard Close from Canaccord Genuity set a price target of $34 for DOCS, suggesting a potential upside of 22.61% from its current trading price of $27.73.
Recently, DOCS experienced a notable drop in its stock price, opening at $23.69 after closing at $33.32. The shares last traded at $25.50, with a trading volume exceeding 4.5 million shares. This decline has led analysts to reassess their ratings. Wall Street Zen downgraded the stock from "buy" to "hold," while Weiss Ratings maintained a "hold (c+)" rating.
Despite the recent price drop, some analysts remain optimistic. Wells Fargo and Company upgraded DOCS to an "overweight" rating, setting a target price of $55.00. Additionally, the Royal Bank Of Canada and Needham and Company LLC both upgraded the stock to a "moderate buy" rating, indicating confidence in the company's future performance.
The stock for DOCS is currently priced at $27.73, reflecting a decrease of 16.78% with a drop of $5.59. Today, the stock has fluctuated between a low of $23.66 and a high of $27.88. Over the past year, the stock has reached a high of $85.21 and a low of $23.66, showing significant volatility.
Doximity's market capitalization is approximately $5.2 billion, and the trading volume today is 22.18 million shares on the NYSE. This high trading volume suggests strong investor interest, despite the recent price fluctuations. As the company navigates these changes, investors will be closely watching for any developments that could impact its stock performance.
